JAMA Network Home
Sign In
Original Investigation

Bicistronic CD19/CD22 CAR T-Cell Therapy in Pediatric B-Cell Acute Lymphoblastic Leukemia

JAMA Oncology 10.1001/jamaoncol.2026.3460

September 03, 2026 at 11:00 AM EDT

Read the full article

In this nonrandomized clinical trial, bicistronic CD19/CD22 CAR T-cell therapy induced high rates of minimal residual disease–negative remission, with durable EFS in pediatric B-ALL. These findings support further evaluation in prospective trials.

Corresponding Author: Ching-Hon Pui, MD, Departments of Oncology, Global Pediatric Medicine, and Pathology, St Jude Children’s Research Hospital, 262 Danny Thomas Pl, Memphis, TN 38105-3678 (ching-hon.pui@stjude.org).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2026.3460?utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=090326

Copy to clipboard

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks